Lapatinib CAS 231277-92-2

Product Description:

Product Name: Lapatinib CAS NO:231277-92-2

Synonyms:

4-{[3-chloro-4-(3-fluoro-benzyloxy)-phenyl]amino}-6-(5-{[(2-methansulfonyl-ethyl)amino]methyl}-furan-2-yl)quinazoline;

N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-furan-2-yl]-4-quinazolinamine;

Chemical & Physical Properties:

Appearance :white powder

Assay :≥98.0%

Density:1.381g/cm3

Boiling Point:750.7℃at 760 mmHg

Flash Point:407.8℃

Lapatinib, trade name Tykerb, is an oral reversible small molecule tyrosine kinase inhibitor targeting HER-1/HER-2. Lapatinib has a different mechanism of action than the humanized monoclonal antibody drug Herceptin, which has been approved for marketing, and can down-regulate cell proliferation signals by double blocking the HER-1/HER-2 pathway. The clinical indication is the combination of capecitabine in the treatment of advanced or metastatic breast cancer with overexpression of HER2 and previous treatments including anthracyclines, taxanes and trastuzumab. The effective rate of advanced first-line monotherapy is about 12~24%, general clinical guidelines recommend second-line medication, and the effective rate of combined treatment with capecitabine is about 26~33%, and the clinical benefit rate is as high as 71.3%, which is the most commonly used Of lapatinib combined with chemotherapy.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.